tert-butyl N-methyl-N-(pent-4-en-1-yl)carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl N-methyl-N-(pent-4-en-1-yl)carbamate
• 英文别名: tert-butyl methyl(pent-4-en-1-yl)carbamate；tert-butyl N-methyl-N-pent-4-enylcarbamate
• 化学式: C₁₁H₂₁NO₂
• 分子量: 199.293
• InChiKey: ZFTGFKQLCVNNJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl N-methyl-N-(pent-4-en-1-yl)carbamate 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以79%的产率得到5-(N-Boc-N-methylamino)-1,2-epoxypentane
  参考文献：
  名称：

  Straightforward synthesis of α,β-epoxysilanes from terminal epoxides by lithium 2,2,6,6-tetramethylpiperidide-mediated deprotonation-in situ silylation

  摘要：

  Lithiation-in situ silylation of simple terminal epoxides using lithium 2,2,6,6-tetramethylpiperidide in combination with trimethylsilyl chloride provides a direct and experimentally convenient process for the synthesis of trans-alpha,beta-epoxysilanes. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(02)01893-2
• 作为产物：
  描述：

  双(叔丁氧羰基)胺 在 sodium hydride 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 46.0h， 生成 tert-butyl N-methyl-N-(pent-4-en-1-yl)carbamate
  参考文献：
  名称：

  Straightforward synthesis of α,β-epoxysilanes from terminal epoxides by lithium 2,2,6,6-tetramethylpiperidide-mediated deprotonation-in situ silylation

  摘要：

  Lithiation-in situ silylation of simple terminal epoxides using lithium 2,2,6,6-tetramethylpiperidide in combination with trimethylsilyl chloride provides a direct and experimentally convenient process for the synthesis of trans-alpha,beta-epoxysilanes. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(02)01893-2

文献信息

• Synthesis of Isomerically Pure (<i>Z</i>)-Alkenes from Terminal Alkynes and Terminal Alkenes: Silver-Catalyzed Hydroalkylation of Alkynes
  作者：Mitchell T. Lee、Madison B. Goodstein、Gojko Lalic

  DOI：10.1021/jacs.9b09336

  日期：2019.10.30

  molecules and often are used as intermediates in organic synthesis. Many alkenes exist in two stereoisomeric forms (E and Z), which have different structures and different properties. The selective formation of the two isomers is an important synthetic goal that has long inspired the development of new synthetic methods. However, the efficient synthesis of diastereopure, thermodynamically less stable, Z-alkenes

  烯烃是一类重要的化合物，常见于生物活性分子中，常被用作有机合成的中间体。许多烯烃以两种立体异构形式（E 和 Z）存在，它们具有不同的结构和不同的性质。两种异构体的选择性形成是一个重要的合成目标，长期以来一直激励着新合成方法的发展。然而，非对映纯、热力学稳定性较差的 Z-烯烃的有效合成仍然具有挑战性。在这里，我们展示了通过银催化的末端炔烃加氢烷基化，使用烷基硼烷作为偶联伙伴，有效合成非对映纯 Z-烯烃（Z:E > 300:1）。我们还描述了对底物范围的探索，这揭示了新方法的广泛官能团兼容性。
• Aryl-Nickel-Catalyzed Benzylic Dehydrogenation of Electron-Deficient Heteroarenes
  作者：Pengpeng Zhang、David Huang、Timothy R. Newhouse

  DOI：10.1021/jacs.9b12706

  日期：2020.1.29

  This manuscript describes the first practical benzylic dehydrogenation of electron-deficient heteroarenes, including pyridines, pyrazines, pyrimidines, pyridazines, and triazines. This transformation allows for the efficient benzylic oxidation of heteroarenes to afford heterocyclic styrenes by the action of nickel catalysis paired with an unconventional bromothiophene oxidant.

  这份手稿描述了缺电子杂芳烃（包括吡啶、吡嗪、嘧啶、哒嗪和三嗪）的首次实用苄脱氢。这种转变允许通过与非常规溴噻吩氧化剂配对的镍催化作用有效地对杂芳烃进行苄氧化以提供杂环苯乙烯。
• [EN] NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME<br/>[FR] NOUVEL INHIBITEUR DE LA TRYPTOPHANE HYDROXYLASE ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT<br/>[KO] 신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물
  申请人：GWANGJU INST SCIENCE & TECH

  公开号：WO2019039905A1

  公开（公告）日：2019-02-28

  신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물에 관한 것으로, 상기 신규한 트립토판 수산화효소 저해제는 TPH1에 대한 저해 효과가 우수한 바, TPH1의 활성과 관련된 질환인 대사질환, 암, 소화기계 질환 또는 순환기계 질환의 예방 또는 치료에 유용하게 사용될 수 있고, 특히, 염증성 장질환의 치료 효과가 우수하므로, 염증성 장질환의 치료에 유용하게 사용될 수 있다.
• [EN] GLYCOCONJUGATES<br/>[FR] GLYCOCONJUGUÉS
  申请人：[en]UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

  公开号：WO2022081895A1

  公开（公告）日：2022-04-21

  Disclosed herein are glycoconjugates having a cell-binding agent, such as an antibody, conjugating to a payload, such as a drug. The drug is conjugated to the cell-binding agent through an oligosaccharide linker. The glycoconjugates conjugated through the oligosaccharide linkers disclosed herein exhibit improved properties over prior glycoconjugates.